In mammalian cells, the Schlafen family of enzymes is known for an unusually drastic antiviral defense: when a virus invades, certain Schlafen nucleases shut down protein synthesis by shredding the cell’s own transfer RNAs (tRNAs), starving the pathogen of the machinery it needs to replicate. Whether bacteria, which pioneered CRISPR-based immunity long before animals existed, possess anything resembling this self-sacrificing antiviral strategy had remained an open question until now. A study published in July 2026 in Nature Communications by Pedro Weickert, Yang Liu, and Jonathan Strecker, of Massachusetts General Hospital and Harvard Medical School, closes this gap by describing a family of prokaryotic Schlafen-related enzymes that answers viral infection with precisely the same drastic logic.
The researchers identify these proteins, named Cash (CRISPR-associated Schlafen), as hybrid enzymes that fuse a Schlafen nuclease domain to Csx15, a previously uncharacterized sensor module related to Rossmann-fold nucleotide-binding proteins. Cash remains dormant until it encounters cyclic tetra-adenylate (cA₄), a signaling molecule generated when the bacterium’s type III CRISPR system detects and degrades an invading phage’s genetic material. Binding of cA₄ arms the enzyme, converting it from an inert particle into an active nuclease that indiscriminately cleaves the cell’s tRNAs, concentrating its cuts within the T-loop and halting translation throughout the infected cell.
The study’s most persuasive evidence comes from cryo-electron microscopy, which captured Cash across three successive states: an inactive twelve-subunit assembly, a filament that forms upon cA₄ binding and aligns multiple catalytic centers into a cooperative cutting apparatus, and a filament caught in complex with a bound tRNA substrate, illuminating precisely how the enzyme recognizes and severs its target.
Beyond this single bacterial system, bioinformatic surveys uncovered numerous additional families of prokaryotic Schlafen-like proteins fused to diverse sensor domains, suggesting that tRNA depletion is not a rare curiosity but rather an ancient, recurring antiviral strategy, independently refined many times across the tree of life, from bacteria defending against phages to human cells resisting viruses such as HIV. This evolutionary convergence strengthens interest in CRISPR-linked signaling nucleases as scaffolds for programmable biosensors or antiviral tools.
Importantly, however, these prospects must be weighed against the fact that the present mechanistic model rests largely on reconstituted biochemistry from a single bacterial species, the Chloroflexi Cash protein, studied outside its native cellular context; whether the broader family of prokaryotic Schlafen proteins identified bioinformatically behaves identically inside living cells, across genuinely diverse hosts and CRISPR subtypes, remains to be established, and this gap between structural elegance and biological generality will determine whether tRNA-cleaving nucleases become a genuinely exploitable tool for antiviral or biosensing technologies.
Leave a Reply